You just read:

CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma

News provided by

CTI BioPharma Corp.

Aug 02, 2017, 01:30 ET